Glioma

Dabrafenib plus trametinib exhibited encouraging activity among patients with recurrent or refractory BRAF V600E mutation-positive glioma, according to study results.

The FDA granted orphan drug designation to CYNK-001 for the treatment of malignant gliomas, according to the agent’s manufacturer.

Use of a modified herpesvirus with and without radiation showed promising efficacy and safety for the treatment of children with recurrent or progressive high-grade glioma, according to results of a phase 1 trial.

OKN-007 received FDA fast track designation for the treatment of children with diffuse intrinsic pontine glioma, or DIPG, according to a press release from the agent’s manufacturer.

Toxoplasma gondii infection appeared to increase the risk for glioma in adults, according to study results published in International Journal of Cancer.

Low-grade glioma is a historically challenging cancer to treat, with some patients succumbing to the disease within weeks of diagnosis and others surviving for decades.

The FDA granted fast track and orphan drug designations to PTC596 for treatment of leiomyosarcoma, according to the agent’s manufacturer.

September is Childhood Cancer Awareness Month.

Phase 1, open-label, interventional trial to determine the adverse effects and best dose of genetically modified T-cell immunotherapy in treating patients with relapsed or refractory malignant glioma.

National Brain Tumor Awareness Month is commemorated in May.